Symyx Technologies, Inc. Launches Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals

SUNNYVALE, CA--(Marketwire - April 22, 2009) - Symyx Technologies, Inc. (NASDAQ: SMMX) today announced the launch of the Symyx Contract Development and Manufacturing Organization (CDMO). The Symyx CDMO helps biopharmaceutical companies move promising drug candidates to clinical trials faster and more reliably with integrated formulation development, and preclinical and CGMP fill/finish manufacturing.

"After discovery, the next critical milestone in drug development is getting to clinical trials quickly with a reliable formulation. The Symyx CDMO provides clients a faster, more reliable route to clinical trials," said Richard Boehner, president of Symyx High Productivity Research (HPR). "We do this by combining unsurpassed formulation expertise, high-productivity research technology and CGMP clinical manufacturing in a single facility."

With expertise in preformulation development, formulation optimization and stability, and analytical method development, the Symyx CDMO enables faster development of highly optimized and robust drug formulations, so that clinical trials test the efficacy of drug candidates, not the limitations of the formulation. In addition, the Symyx CDMO offers full service fill/finish execution for delivering drug products manufactured under CGMP conditions while maintaining the integrity of drug substances and meeting preclinical and Phase I and II clinical trial schedules.

Symyx has more than a decade of experience helping clients -- from small biotechnology start-ups to the large pharmaceutical companies -- develop stable, robust drug formulations. Byeong Chang, chief scientific officer of the Symyx CDMO, is a pioneer and industry leader in large-molecule formulation development, with nearly two decades of biopharmaceutical experience.

"Symyx has a history of accelerating drug formulation breakthroughs, performing formulation development for more than 70 companies, and successfully completing 80 formulation projects," said Chang. "With more than 120 years of collective formulation development experience, the Symyx CDMO team has the experience biotechnology and pharmaceutical companies need to achieve critical drug development milestones."

Symyx Technologies is an innovative pioneer in microscale, parallel experimentation and advanced scientific informatics to deliver better formulations faster from less drug substance. The company has more than 300 patents covering its software, equipment and processes.

For more information on the Symyx CDMO visit http://www.symyx.com/CDMO or contact biopharm.info@symyx.com.

About Symyx

Symyx Technologies, Inc. (NASDAQ: SMMX) enables companies in life sciences, chemicals and energy, and consumer and industrial products to transform scientific R&D and achieve extraordinary breakthroughs in productivity and return on investment. Symyx scientific information management enables scientists to design, execute, analyze, and report experimental results faster, easier, and less expensively. Symyx microscale, parallel experimentation enables a single scientist to rapidly explore a broad experimental space and develop comprehensive data sets in days -- not weeks or months. Symyx contract research delivers these advantages on a project basis and enables companies to increase R&D productivity, agility, and flexibility. Information about Symyx, including reports and other information filed by Symyx with the Securities and Exchange Commission, is available at www.symyx.com.